ADO and lung carcinoma: This study therefore focused on elucidating the underlying mechanisms of resistance to immune checkpoint inhibitors associated with the ADO signaling pathway (Figure 2) as well as exploring the potential of ADO pathway inhibitors in overcoming immune resistance in lung cancer.